Hemmel Amrania PhD Breast Cancer Diagnostics
About Hemmel Amrania PhD Breast Cancer Diagnostics
Hemmel Amrania, PhD, serves as the Chief Executive Officer of Digistain and has extensive experience in cancer diagnostics. He has developed innovative solutions for breast cancer treatment and holds multiple patents, awards, and academic degrees in physics and optics.
Work at Digistain
Hemmel Amrania serves as the Chief Executive Officer at Digistain, a position he has held since 2020. Under his leadership, the company focuses on developing innovative solutions for breast cancer diagnostics. He designed a Quality Management System in accordance with ISO 13485 for a tumour profiling laboratory, ensuring compliance with international standards. His work has contributed to addressing economic and patient care challenges in the field of cancer diagnostics.
Education and Expertise
Hemmel Amrania holds a Physics PhD from Imperial College London, where he focused on the biomedical applications of ultrafast laser spectroscopy. He also earned a Physics MSci and a Masters in Optics and Photonics from Université Paris XI. His educational background provides a strong foundation in cancer research and biomedical imaging, which informs his work in diagnostics and technology development.
Background
Amrania's career includes significant roles in various organizations. He worked at Y Combinator as part of the YC Summer 21 Batch in 2021. He has held positions at Imperial College London as a Physicist in Cancer Diagnostics Development since 2017, and previously worked as a Medical Technology Consultant at Imperial Innovations Investment Management. His experience also includes roles at Charing Cross Hospital and Cancer Research UK, where he contributed to clinical research.
Achievements
Hemmel Amrania has received multiple accolades for his contributions to cancer diagnostics. He was awarded the Outstanding Research Prize and the President’s Award for Outstanding Research at Imperial College London. He has also received the Royal Innovation Award and the Cancer Research Pioneer Award. His work has led to the generation of seven technology patents and the successful completion of a study involving 800 patients for invasive breast cancer.
Research and Development Contributions
Amrania has developed practical solutions for oncologists to enhance treatment decisions, which were integral to the creation of Digistain. He secured over £1 million in seed funding for a tumour profiling laboratory and achieved MHRA market clearance and CE Marking for the laboratory. His patented method for grading tumour biopsies aims to eliminate subjective bias, showcasing his commitment to advancing cancer diagnostics.